Ndovu study: best HIV treatment for drug resistance
Part of Infections clinical trials.
This trial is for people with HIV who are not responding well to the drug dolutegravir (DTG). It tests if switching to a different drug, darunavir/ritonavir (DRV/r), works better than continuing DTG when resistance has developed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are already part of the Ndovu cohort study
- You are 3 years old or older
- Your most recent HIV viral load is at least 200 copies/mL
- Blood tests show that the HIV virus has become resistant to dolutegravir (a specific type of gene change)
- You are not pregnant or breastfeeding
- You do not have a serious opportunistic infection (like advanced AIDS) that would prevent you from safely joining
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
This study looks at how drug resistance mutations in HIV might affect how well certain treatments work, including two-drug regimens. It aims to help doctors choose the best medicines for each person.
This study sees if it's safe to switch your current HIV medication to a two-pill combo (dolutegravir and lamivudine) if you are also taking medication for opioid addiction. It aims to make treatment simpler and more convenient.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.